Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should KnowZacks Investment Research • Tuesday
Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research • 11/07/24
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024PRNewsWire • 11/07/24
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024PRNewsWire • 11/05/24
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary AngioedemaPRNewsWire • 10/24/24
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with RochePRNewsWire • 10/17/24
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024PRNewsWire • 10/03/24
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma PatientsPRNewsWire • 09/27/24
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple MyelomaPRNewsWire • 09/16/24
Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024Seeking Alpha • 09/09/24
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual MeetingPRNewsWire • 09/05/24
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple MyelomaPRNewsWire • 09/04/24
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/24
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024PRNewsWire • 08/05/24
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great ChoiceZacks Investment Research • 07/19/24
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy ForumPRNewsWire • 07/01/24
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024PRNewsWire • 05/14/24
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingPRNewsWire • 05/09/24
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyPRNewsWire • 05/02/24
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingPRNewsWire • 04/18/24